News Releases

Stay up to date with SMPA

The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.

Month Year

Get News Alerts by Email

Jan 19, 2023

Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options

•Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign

IRVINE, Calif. & ZUG, Switzerland – January 19, 2023 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma, Ltd., today announced its partnership with actress and overactive...
Nov 14, 2022

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

•Urovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB)

IRVINE, Calif. & BASEL, Switzerland – November 14, 2022 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel...
Nov 1, 2022

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

First Trial to Study a Trace Amine-Associated Receptor 1 (TAAR1) Agonist in Major Depressive Disorder (MDD)

PRINCETON, M.J. & MARLBOROUGH, MASS. – December 1, 2022 – Otsuka Pharmaceutical Development & Commercialization, Inc.(Otsuka) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced that...
Aug 5, 2022

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

•Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment

BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...
Jul 5, 2022

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

•Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland.

Basel, Switzerland, and Castres, France – July 5, 2022 — Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., and Pierre Fabre Médicament today announced they have...

Show per page